Best in Biotech 18 May 2023 Six women’s health companies you should know about While sexism exists in all strands of society, where in 2023, women earn 77 cents for every dollar earned by men, studies estimate that it will take the world 257 years to close the gender gap. And the global healthcare industry is partly to blame when it comes to the gaping gender gap. Women have […] May 18, 2023 - 8 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
More News! 10 Dec 2019 ObsEva’s Oral Treatment for Uterine Fibroids Nails Phase III An oral drug developed by the Swiss company ObsEva was shown to reduce menstrual bleeding and pain caused by uterine fibroids. The phase III trial tested ObsEva’s drug candidate linzagolix in 535 women suffering from heavy menstrual bleeding caused by benign tumors in the uterus called uterine fibroids. The effects of the drug were compared […] December 10, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 27 Feb 2018 Successful Phase III Results for Swiss Biotech ObsEva’s Drug for In Vitro Pregnancy Yesterday, Swiss biotech ObsEva highlighted positive Phase III results that show their fertility treatment nolasiban improved the pregnancy rate of women following in vitro fertilization. ObsEva, a clinical stage, Geneva-based biopharmaceutical company dedicated to women’s reproductive medicine, states that current Phase III results for the drug show an increase in pregnancy rate of 32 % after […] February 27, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Interview 26 Jun 2017 Meet the Gynecologist at the Helm of Geneva’s Star Biotech Ernest Loumaye began as a doctor at a university hospital and is now CEO of ObsEva. We chatted about how biotech supports women’s health. ObsEva, one of the top biotechs in Geneva that made this year’s first IPO for a huge €90M, is not Ernest Loumaye’s first company. Though he began as the gynecologist in charge of the reproductive […] June 26, 2017 - 5 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Best in Biotech 30 May 2017 In Geneva, the Capital of Peace, 10 Biotechs Are Putting up a Fight Geneva is the largest city in French-speaking Switzerland, a financial powerhouse, home to the United Nations and known as the “Peace Capital.” Can the city’s biotech industry justify its high profile? Geneva rose to recognition as a biotech hub in 2006, when Serono sealed its acquisition by Merck in the city’s biggest-ever licensing plan. However, a late-stage […] May 30, 2017 - 7 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
More News! 7 Mar 2017 UPDATE: Reproductive Health Biotech starts Phase III after €90M IPO UPDATE (07/03/2017): ObsEva has announced the start of its Phase III trials for nolasiban, an oral oxytocin receptor antagonist. It is under evaluation for improvements in pregnancy and live birth rates following embryo transfer (ET). UPDATE (26/01/2017): ObsEva has disclosed plans to release 6.45M shares at $15 (€14) each, for a total of €90.3M. This large total reflects […] March 7, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email